{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:02:08Z","timestamp":1787950928882,"version":"build-2784847793"},"reference-count":27,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study is to review the available data on efficacy and tolerability of tazarotene 0.045% lotion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A literature search of MEDLINE (PubMed) and EMBASE databases was completed in November 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Articles that discussed efficacy, tolerability, and pharmacology of tazarotene 0.045% lotion, written in English and published before mid-November 2021, were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>\n                      In two, 12-week phase III clinical trials, tazarotene 0.045% lotion had higher rates of treatment success (study 1: 25.5% and study 2: 29.6%) than individuals who received the vehicle (study 1: 13.0% and study 2: 17.3%) (both\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      s &lt; 0.001). Participants treated with tazarotene 0.045% lotion had greater least squares mean reduction in inflammatory (study 1: 55.5% and study 2: 59.5%) and noninflammatory (study 1: 51.4% and study 2: 60%) acne lesions when compared with vehicle (inflammatory acne lesions, study 1: 45.7% and study 2:49%; noninflammatory acne lesions, study 1: 41.5% and study 2: 41.6%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 for studies 1 and 2). Tazarotene 0.045% lotion was well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>Retinoids are first-line therapy in the treatment of acne vulgaris. However, many patients experience cutaneous irritation, which can decrease patient adherence and efficacy. Tazarotene 0.045% lotion is the first retinoid to utilize polymeric emulsion technology (PET) to efficiently distribute the medication across the skin, decreasing adverse effects while maintaining efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tazarotene 0.045% lotion is an effective and well-tolerated retinoid recently approved by the US Food and Drug Administration (FDA) for treating acne vulgaris in individuals 9 years of age and older.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280211072155","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T05:23:53Z","timestamp":1643865833000},"page":"1174-1180","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Tazarotene 0.045% Lotion: A Novel Retinoid Formulation"],"prefix":"10.1177","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-8888","authenticated-orcid":false,"given":"Lindsey A.","family":"Mohney","sequence":"first","affiliation":[{"name":"College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Social Sciences &amp; Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Social Sciences &amp; Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/AHMT.S55832."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21081063."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.045."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-0490B."},{"issue":"6","key":"e_1_3_2_6_2","first-page":"12","article-title":"40 years of topical tretinoin use in review","volume":"12","author":"Baldwin HE","year":"2013","unstructured":"Baldwin HE, Nighland M, Kendall C, Mays DA, Grossman R, Newburger J. 40 years of topical tretinoin use in review. J Drugs Dermatology. 2013;12(6):12-15.","journal-title":"J Drugs Dermatology"},{"issue":"8","key":"e_1_3_2_7_2","first-page":"475","article-title":"Acne vulgaris: diagnosis and treatment","volume":"100","author":"Og\u00e9 LK","year":"2019","unstructured":"Og\u00e9 LK, Broussard A, Marshall MD. Acne vulgaris: diagnosis and treatment. Am Fam Physician. 2019;100(8):475-484.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13340."},{"issue":"12","key":"e_1_3_2_9_2","article-title":"Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments","volume":"17","author":"Chien A.","year":"2018","unstructured":"Chien A. Retinoids in acne management: review of current understanding, future considerations, and focus on topical treatments. J Drugs Dermatol. 2018;17(12):s51-s55.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11100490."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.078."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.3977."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06741.x."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1309349."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.03.013."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0185-2."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.108321."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(98)70310-x."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0065-1."},{"issue":"6","key":"e_1_3_2_21_2","first-page":"542","article-title":"A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris","volume":"18","author":"Tanghetti EA","year":"2019","unstructured":"Tanghetti EA, Kircik LH, Green LJ, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519847367."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.4869."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.012"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.5.605."},{"key":"e_1_3_2_26_2","unstructured":"GoodRx. Retinoids. Published October 27 2021. Accessed December 29 2021. https:\/\/www.goodrx.com\/retinoids."},{"key":"e_1_3_2_27_2","unstructured":"GoodRx. Arazlo. Published September 12 2021. Accessed December 29 2021. https:\/\/www.goodrx.com\/arazlo."},{"key":"e_1_3_2_28_2","unstructured":"GoodRx. Compare Differin Gel prices. Published September 12 2021. Accessed December 29 2021. https:\/\/www.goodrx.com\/differin-gel?dosage=45g-of-0.1%25&form=tube-of-gel&label_override=DifferinGel&quantity=1&sort_type=popularity."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211072155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280211072155","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280211072155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:40Z","timestamp":1777375000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280211072155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10600280211072155"],"URL":"https:\/\/doi.org\/10.1177\/10600280211072155","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}